The NEES PLA + HA Filler listing describes a hybrid injectable containing 170 mg PLA and 30 mg HA, a composition commonly associated with the 200 mg Etrebelle presentation.

That identity should be confirmed on the physical pack because NEES also lists a PLA + HA Soft Tissue Injectable Implant, and the site does not establish whether the two entries represent distinct products.

Catalogue visual: PLA + HA Filler from the NEES Medical product catalogue. Packaging appearance alone does not establish authenticity; verify the supplied batch, expiry, seals and traceability documents.

What it is

This catalogue entry is positioned as a high-viscosity hybrid of poly-D,L-lactic acid and hyaluronic acid. Public Etrebelle instructions describe a lyophilized PLA/HA soft-tissue implant, while secondary market listings commonly report a 170 mg plus 30 mg combination. Because dosage strength and trade name are safety-critical, buyers should not rely on a generic title: the sealed pack, manufacturer instructions and applicable registration documents must agree.

Market position and alternatives

Market positioning emphasizes the combination of early support and delayed biostimulation, but product choice depends on anatomy, correction goal, reversibility needs and practitioner experience.

Potential advantages

• The disclosed 170 mg PLA and 30 mg HA claim gives clinics a concrete specification to verify against the pack.
• The hybrid concept may bridge some immediate correction and longer-term tissue-remodelling goals.
• A regulator-hosted Etrebelle document is available for cross-checking core product identity.
• The category encourages explicit counselling about staged results rather than promising a single immediate endpoint.

Limitations and buying considerations

• Independent product-specific comparative evidence is limited, so strong superiority claims are not justified.
• Delayed reactions or nodules can occur with collagen-stimulating materials and may not follow the same management pathway as HA alone.
• The duplicated or overlapping NEES entries could lead to strength, presentation or documentation errors.
• A European safety notice on counterfeit Etrebelle devices makes supply-chain verification more important than headline price.

Quality and authenticity checklist

• Require the trade name and exact 170 mg PLA plus 30 mg HA statement on the current pack if that is the product being quoted.
• Compare carton design, manufacturer details, lot, expiry and security elements with regulator or manufacturer documentation.
• Reject repacked, unlabelled or mixed-lot vials and retain invoice and packaging photographs.
• Verify that the quotation and clinical record distinguish this listing from the separate soft-tissue implant page.

Price and availability in Pakistan

The PLA + HA Filler price in Pakistan is available by quotation from NEES Medical; no verified numeric PKR price is shown in the live catalogue. Before accepting a quote, request the trade name, composition, pack size, batch, expiry and current availability in writing.

Sources and further reading

• ANMAT — Etrebelle Instructions for Use and Label
• Polish URPL — Etrebelle Counterfeit Medical Device Safety Notice
• Long-Term Correction of Nasolabial Folds Using PLLA Microspheres

View the PLA + HA Filler catalogue page or request current pricing and availability.